Optimal regimens for the treatment of invasive fungal infections have yet to be defined, and these life-threatening conditions are one of the leading causes of treatment failure in patients with cancer. A substantial body of preclinical work points in the direction of using cytokines as immunomodulators of the multiple deficiencies involved in the progression of fungal infections in neutropenic and nonneutropenic cancer patients. These deficiencies include not only the easily recognized deficiencies in cell quantity but also subtle deficiencies of cell function. Four cytokines (granulocyte colonystimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon g) show promise as adjuvant therapy for proven fungal infections in this setting, although clinical experience is still limited. As an additional approach, the concept of white blood cell transfusions has been revived by the use of granulocyte colony-stimulating factor and promises to be helpful in the setting of neutropenia.
The most important element of the host response to fungal While noteworthy progress has been achieved in the treatinfection varies in relation to the fungi. For such endemic ment of patients with cancer over the past decade, especially mycoses as Cryptococcus neoformans, Paracoccidioides brain terms of achieving substantial control over bacterial infecsiliensis, Coccidioides immitis, and Histoplasma capsulatum tions by use of potent antibiotics [1 -3], infection still remains infections, cell-mediated immunity appears to be critical [9 -a frequent cause of treatment failure. In particular, fungal infec-13]. Recent data also suggest at least a partial role for humoral tions have become one of the leading factors contributing to immunity in defense against cryptococcosis [14] and candidiamorbidity and mortality in immunosuppressed patients [4 -7] .
sis [15 -17] . Conversely, neutropenia has long been recognized Candida and Aspergillus species have been consistently noted as the most important risk factor for invasive candidiasis, asperas the most important fungal pathogens. A large autopsy series gillosis, and other mold infections such as fusariosis [18 -20] . of patients with cancer found that 58% of fungal infections Normal phagocytic cells can ingest and kill Aspergillus as were caused by Candida species and 30% by Aspergillus spewell as Candida organisms [21 -24] , but these functions are cies [5] .
decreased in patients with acute leukemia because of a decrease A similar study of bone marrow transplantation (BMT) pain the function of circulating phagocytes [25 -27] as well as tients showed that the incidence of invasive aspergillosis among in the number of cells seen after initiation of chemotherapy. It them increased from 5.7% to 11.2% (1987 to 1993) [7] , while has recently become clear, however, that neutropenia is not the in a smaller study of patients with hematologic malignancies sole relevant factor; these invasive mycoses have increasingly it increased from 7% to 21% [6] . The mortality associated with been noted in patients who have normal polymorphonuclear invasive aspergillosis in BMT patients, even after engraftment, leukocyte (PMNL) counts. This group includes patients with was close to 90% despite maximal antifungal therapy [8] . Such lymphoma, transplant recipients, those undergoing certain cytofindings are not encouraging and reflect the severe loss of toxic chemotherapy regimens, patients with AIDS, and neohost defenses in these patients, as well as the relatively poor nates [28 -35] . performance of currently available antifungal agents in such Secondary risk factors in these nonneutropenic patients insituations. Novel therapeutic strategies are urgently needed.
volve several different defects. First, lymphoid and hematopoietic malignancies such as Hodgkin's disease and hairy cell leukemia may be associated with defective cell-mediated immunity
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therapy not only induces aplasia but also impairs cell-mediated motaxis [40 -42] , altered opsonization [43] , lymphopenia [44] , recovery of the patient's bone marrow function [65, 66] as well as by permitting novel approaches to transfusion therapy. The defective response of T cells to antigens [45] , altered synthesis of IFN-g [46, 47] , and decreased phagocytosis by pulmonary potential relevance of these concepts for invasive candida and aspergillus infections has only recently begun to be studied alveolar macrophages. In this population, these multiple defects combine to increase the risk for aspergillosis, and this risk [67 -70] , and a brief review of the relevant cytokines is in order. appears to persist, even after successful engraftment. A recent study conducted at M.D. Anderson Cancer Center (Houston) of patients undergoing CD3
/ T cell -depleted matched unrelated
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BMT found that 52% of deaths (11 of 21) were caused by refractory fungal infections, particularly aspergillosis, and that IFN-g, a polypeptide secreted by T lymphocytes, NK cells, alveolar macrophages, and fibroblasts, is the main cytokine most of these infections occurred in patients who had recovered from myelosuppression [8] .
produced during a Th1-type response. IFN-g is approved for administration to humans and has been shown to enhance the An additional secondary risk factor concerns the corticosteroids used to treat malignancies, graft-vs.-host disease, and oxidative metabolism and antifungal activity of human macrophages and PMNLs in vitro against a broad range of relevant other conditions that induce macrophage dysfunction and increase the risk of invasive fungal infections [48] 51] . As exogenous cytokines have the potential for correcting many of these defects, there has been substantial interest ity by T lymphocytes and NK cells [75] ; it also appears to be of benefit as an in vivo adjunct when given either prophylacin their use as adjuvant therapy for invasive fungal infections in cancer patients.
tically or after establishment of experimental infections with A. fumigatus [76] and C. neoformans [77] . IFN-g was also shown to at least partially correct the oxidaThe Potential Therapeutic Role of Cytokines tive burst in a group of patients with chronic granulomatous disease [78, 79] , although this in vitro effect was not seen The innate host defense against fungal diseases is based on the action of phagocytic cells (PMNLs and macrophages) [51] ; consistently in a subsequent placebo-controlled clinical trial [80] (see below). IFN-g is generally well tolerated when given both the number and the function of these cells can be regulated by the colony-stimulating factors (CSFs). On the other hand, to humans, although a transient, dose-dependent flu-like syndrome with fever, chills, headache, fatigue, myalgias, arthralacquired defense involves cellular and humoral immunity that requires interactions between antigen-presenting cells, T lymgias, and erythema at the site of injection is frequently seen [80, 81] . phocytes, B lymphocytes, and NK cells that are driven and regulated by cytokines such as IL-2 and IFN-g [51, 52] .
The potential importance of immune activation via cytokines
The CSFs in the host defense against opportunistic fungi has been the subject of several studies [51, 52] and has raised some intriguThree CSFs relevant to phagocytes are licensed for administration to humans: G-CSF, GM-CSF, and macrophage colonying questions about novel antifungal strategies for candida and aspergillus infections. Different potential roles for cytokines stimulating factor (M-CSF). CSFs are responsible not only for the replication of bone marrow stem cells but also for the have been described. First, exposure to fungi and their antigens may induce release of IL-2, IFN-g, tumor necrosis factor-a differentiation of granulocytes and monocytes into their mature forms [82] . Cellular sources of these powerful cytokines in-(TNF-a), granulocyte colony-stimulating factor (G-CSF), and granulocyte macrophage colony-stimulating factor (GM-CSF) clude monocytes, T lymphocytes, fibroblasts, and endothelial cells [83] . CSFs enhance chemotaxis, phagocytosis, and killing [12, 52 -57]. These cytokines may in turn activate or enhance the antifungal function of phagocytes against Candida [58 - activity of precursor and mature effector cells [84] . These three CSFs have been shown in multiple studies to 61] and Aspergillus species [62 -64] .
In addition, exogenous administration of at least some of enhance the activity of phagocytic cells against Candida species, A. fumigatus, C. neoformans, and H. capsulatum [58, 59, these agents is now possible, thus permitting therapeutic bypass of the need for direct host response. As cytokines exert their 62 -64, 74, 85 -88] . In addition, G-CSF has been shown to protect PMNLs from the deleterious effects of isolation and effect indirectly, via activation of a leukocyte rather than by any direct action on the fungus, they are most effective if there irradiation [89, 90] . These effects have taken on special importance in recent studies reassessing the utility of WBC transfuare adequate numbers of circulating leukocytes. Cytokines can be used to ensure adequate numbers of leukocytes by speeding sion [91] . . GM-CSF also prolongs the life span IL-12 is a proinflammatory cytokine produced by phagocytic cells, by dendritic cells, and at lower levels by keratinocytes and enhances the antibody-dependent cytotoxicity of eosinophils [94] . In addition, GM-CSF promotes the differentiation and nonmucosal mast cells. IL-12 induces T and NK cell proliferation and production of Th1-type cytokines (IFN-g, GMand proliferation of the cells of the macrophage-monocyte system [95, 96] . This activity is lacking in G-CSF; thus, CSF, TNF, and IL-2) [121] . Several animal models have shown that the neutralization of IL-12 increases the severity of infec-GM-CSF would have a theoretical advantage in infections where monocyte-macrophage function is critical. Although fortions produced by H. capsulatum [122] , C. immitis [123] , and C. albicans [124] . On the other hand, exogenous IL-12 has mal proof is lacking, G-CSF appears to be more potent than GM-CSF in increasing the neutrophil production rate [97, 98] .
been shown to be beneficial in mice with cryptococcosis [125], coccidioidomycosis [123] , and histoplasmosis [126] but not in M-CSF, as expected, stimulates survival, proliferation, differentiation, and activation of progenitor and mature cells of the cases of candidiasis [127] or aspergillosis [128] . The neutralization of the two major cytokines that charactermonocyte/macrophage lineage [99] . However, M-CSF also affects granulocytes via indirect mechanisms comprising stimulaize a Th2-response, IL-4 and IL-10, may be an additional approach for adjuvant treatment against fungal infections. Both tion of production of G-CSF and GM-CSF [100] .
The CSFs are approved for clinical use but can have serious cytokines have been proven to decrease the antifungal activity of macrophages against C. albicans [129] and of IL-10 against side effects. For GM-CSF, the side effect profile depends on whether the compound is expressed in a bacterial vector, a
Aspergillus species [130] . In animal models the neutralization of these cytokines improved survival of mice infected with yeast, or a mammalian system and whether or not it is glycosylated [101] . Two preparations of GM-CSF are commercially C. albicans [127, 131, 132] . A similar model with IL-4 showed the same pattern in invasive aspergillosis [128] . available: a glycosylated yeast-derived form and, in Europe, a nonglycosylated Escherichia coli -derived form. The first dose of the nonglycosylated form has been associated with transient Clinical Applications of Cytokines in Fungal Infections dyspnea, oxygen desaturation, flushing, tachycardia, hypotension, myalgias, nausea, and vomiting [102] . These phenomena
Cytokines as Adjuvant Therapy
are seen less often with the glycosylated form [101, 103 -105] . Myalgias and bone pain are the principal side effects of GDespite this intriguing body of preclinical data, establishing the clinical utility of cytokines as therapy for fungal infections CSF [106] , while the main toxic effects associated with use of M-CSF have been bone pain and thrombocytopenia [99] .
in cancer patients has been difficult. Three basic strategies have been pursued: use of cytokines at induction of neutropenia in high-risk patient groups, use of cytokines as part of the therapy
Other Cytokines
for febrile neutropenic patients, and use of cytokines in defined fungal infections. While not approved by the U.S. Food and Drug Administration and perhaps too toxic for routine use, TNF-a is a proinProphylaxis during neutropenia. The most convincing information available comes from controlled trials of G-CSF flammatory cytokine produced by PMNLs, macrophages, monocytes, keratinocytes, T and B lymphocytes, NK cells, and GM-CSF administered for amelioration of leukopenia after cytotoxic chemotherapy [65, 105, 133 -136] . Both compounds astrocytes, and endothelial cells [107, 108] . It has been shown to have diverse properties, including activation of PMNLs, have been shown to reduce the duration of severe neutropenia, which, in turn, has led to fewer hospital admissions for fever enhancement of phagocytosis and microbicidal activity, activation of eosinophils, and stimulation of fibroblast growth [61, and neutropenia, less use of antimicrobial agents, and fewer documented infections [103] . Unfortunately, there were not 109, 110] . The in vitro ability of TNF-a to augment the fungicidal capacity of macrophages and PMNLs against Candida enough fungal infections in the placebo-treated groups of any of these studies to permit even a limited estimate of the potenspecies, C. immitis, and C. neoformans has been demonstrated in a variety of experiments [111, 112] . Release of TNF-a by tial of the cytokines in the prevention and/or treatment of fungal infections. macrophages and peripheral blood mononuclear cells in response to Candida and Aspergillus species organisms has also Empirical therapy for febrile neutropenic patients. Patients with fever and neutropenia have been enrolled in 5 controlled been demonstrated [113 -115] .
Another candidate cytokine, IL-2, is a powerful proinflamtrials -3 of GM-CSF, 1 of G-CSF, and 1 of both agentsthat have been described in the literature [106, 137 -140] . matory cytokine produced by T cells [116] . Interleukin-2 promotes proliferation of lymphocytes and enhances the function While these studies collectively demonstrated that cytokines tend to shorten the duration of severe neutropenia, the effect of cytotoxic T lymphocytes and NK cells. IL-2-activated lym-/ 9c4e$$ju42 05-12-98 14:09:58 cida UC: CID on fever and clearance of infection was less obvious. In addithis manner against Leishmania major [144] and Toxoplasma gondii [145] . tion, the use of cytokines neither reduced the need for antimicrobial agents nor affected the outcome of infection. There
Use in other settings. Because of the potential of CSFs to reverse leukopenia, the studies of cancer patients have focused were too few defined fungal infections to permit any conclusions to be drawn about the utility of CSFs for these infections. mostly on use of CSFs. Outside of the cancer arena, the broadbased immune activation produced by IFN-g has attracted subTherapy for defined fungal infections. In a pilot trial by Bodey and colleagues, eight patients with documented refracstantial interest as well. The usefulness of IFN-g prophylaxis in patients with chronic granulomatous disease was examined tory fungal infections were treated with glycosylated GM-CSF plus amphotericin B [66] . The conditions of 4 of 5 patients in one of the largest single studies of cytokines to date [80] . In this study, 367 patients were randomized to receive either with candidiasis, 1 of 2 with aspergillosis, and the 1 with trichosporonosis improved with this therapy. GM-CSF was placebo or IFN-g at a dose of 50 mg/m 2 three times a week. Clinically, systemic IFN-g prophylaxis produced a 72% reused at a relatively high dose in this study (400 mg/[m 2 rd]); thus, it is not surprising that the major side effect was the duction in the risk for serious infections, compared with the risk with placebo. While this effect was primarily due to the capillary leak syndrome. Given the limited nature of the study and the lack of a comparison group, no conclusions about reduction in the rate of bacterial infection, aspergillus pneumonia was somewhat less common in the patients receiving IFNefficacy can be drawn.
Similarly, in a 1993 study by Nemunaitis and colleagues, a g (4 of 65 placebo-treated patients vs. 1 of 63 IFN-g-treated patients; OR, 4.1; 95% CI, 0.5 -32). Although these numbers series of patients with a variety of types of cancer were given M-CSF combined with an antifungal agent as therapy for an are too small to permit strong conclusions, a parallel blinded study that examined the ex vivo function of PMNLs in the invasive fungal infection (30 patients had candida infections, 15 had aspergillus infections, and 1 had a mucor infection) same group of patients found that in the placebo-treated patients there was a decrease over time in the ability of PMNLs to [100] . Several different doses of M-CSF were studied, and all demonstrated a slight trend toward an increased WBC count.
damage Aspergillus hyphae, while in the IFN-g-treated patients there was an increase in their function [146] . These results, Patients who received higher doses of M-CSF developed thrombocytopenia, although this was not clinically significant. along with several case reports describing a potential role for adjunctive IFN-g therapy for refractory invasive fungal infecGreater survival was observed among patients with candida infections and a Karnofsky score of ú20%, compared with the tion, suggest that this particular cytokine might play a useful role in some settings [147 -150] . figures for historical controls. As with the study by Bodey and colleagues [66] , unfortunately this nonrandomized study provided few data on the effect of the cytokine on the course of fungal infection.
Cytokine-Enhanced WBC Transfusions
Finally, several case reports have shown that G-CSF and GM-CSF appeared helpful as part of a combined regimen for As purely cytokine-based therapies are dependent on the presence of WBCs, profoundly cytopenic patients would be fusariosis and trichosporonosis in selected cancer patients [141 -143] .
expected to derive little benefit from these therapies. WBC transfusions have long represented a tantalizing solution to Prevention of fungal and other infections. Significant morbidity and mortality are associated with invasive fungal this problem. Unfortunately, this concept is beset by many difficulties [151, 152] , not the least of which are the dual infections in patients who have apparently adequate neutrophil counts. Cytokines, particularly IFN-g, GM-CSF, and Gproblems of (1) collecting adequate numbers of cells from the donor and (2) the limited persistence of the transfused cells. CSF, increase the number and/or stimulate the function of phagocytic cells. It is tempting to speculate that the use of Cytokines do, however, permit at least partial solutions to both of these problems. First, the problem of collecting an these cytokines as prophylactic agents in this setting might be valuable. More specifically, GM-CSF or G-CSF, alone or adequate number of donor cells has long been addressed by treating the donor with a corticosteroid [153, 154] . However, in combination with IFN-g, could be used immediately after engraftment following allogeneic BMT or even autologous such therapy has the theoretical disadvantage of suppressing leukocyte function (see above), and this problem might be BMT in certain settings. These agents could thus be used to stimulate phagocytic cells and hence decrease the morbidity better solved by administering G-CSF or GM-CSF to the WBC donor. Second, PMNLs are triggered upon isolation to begin the and mortality associated with aspergillosis, which has become the leading cause of death of these patients. A prospective process of programmed cell death, or apoptosis. As apoptotic PMNLs are rapidly removed from the circulation [155] , this randomized trial evaluating the role of GM-CSF after engraftment is currently in preparation.
may account for some of the problems with cell persistence after isolation and transfusion. Here again, recent work has As an additional approach, either IL-12 or IL-15 might be administered in combination with crude fungal antigen to inshown that multiple cytokines, including G-CSF and IFN-g, can reduce apoptosis and preserve PMNL function [156, 157] . duce a protective immune response such as that produced in / 9c4e$$ju42 05-12-98 14:09:58 cida UC: CID
The clinical consequences of these ideas have been explored fusion, but the high level of function of these cells is sufficient to produce a strong clinical response. in a recent series of studies. First, a detailed set of in vitro experiments has shown that treatment of normal PMNLs with
The next steps in evaluating the cytokines as therapy for fungal infections will require carefully designed comparative physiological doses of G-CSF or of IFN-g plus G-CSF reduced apoptosis, preserved surface-receptor expression, and prestudies. As these agents are expensive and have the potential for inducing drug-related side effects as well as possibly worsening served the ability to kill C. albicans [89, 90] . As transfused blood products are often irradiated to prevent graft-vs.-host graft-vs.-host disease, their use on a broad scale should not proceed without substantial additional investigation. Such trials disease, these studies also examined PMNLs after irradiation and found that these cytokine regimens also ameliorated the are going to be difficult, but the initial data are sufficiently promising that every effort to pursue such studies should be consequences of exposure to the standard irradiation dose of 30 Gy. Regimens that included GM-CSF instead of G-CSF made. were not protective.
Of further interest, PMNLs collected from healthy individuals treated with G-CSF were found to behave in much the same ation. The in vivo consequences of these ideas can be seen in were treated with G-CSF-mobilized granulocytes from normal develops an invasive fungal infection (e.g., is invasive aspergil-14. Casadevall A, Scharff MD. Return to the past: the case for antibodybased therapies in infectious diseases. Clin Infect Dis 1995; 21: losis after marrow transplant engraftment related to inadequate 159 -61. function?) and by the intriguing early data on G-CSF-elicited 15. Matthews R, Burnie J. Acquired immunity to systemic candidiasis in WBC transfusions. In the first situation, the patient has a suffi- 
